Amgen Inc. (NASDAQ:AMGN) Stock Holdings Raised by Smead Capital Management Inc.

Smead Capital Management Inc. raised its stake in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 3.5% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 1,172,866 shares of the medical research company's stock after acquiring an additional 39,559 shares during the period. Amgen makes up 5.4% of Smead Capital Management Inc.'s investment portfolio, making the stock its 6th biggest holding. Smead Capital Management Inc. owned 0.22% of Amgen worth $377,909,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Verity & Verity LLC raised its stake in shares of Amgen by 0.7% during the 3rd quarter. Verity & Verity LLC now owns 87,595 shares of the medical research company's stock worth $28,224,000 after buying an additional 618 shares in the last quarter. Meeder Asset Management Inc. raised its stake in shares of Amgen by 14.7% during the 3rd quarter. Meeder Asset Management Inc. now owns 53,443 shares of the medical research company's stock worth $17,220,000 after buying an additional 6,835 shares in the last quarter. Belmont Capital LLC raised its stake in shares of Amgen by 88.0% during the 3rd quarter. Belmont Capital LLC now owns 1,139 shares of the medical research company's stock worth $367,000 after buying an additional 533 shares in the last quarter. Caprock Group LLC raised its stake in shares of Amgen by 6.6% during the 3rd quarter. Caprock Group LLC now owns 16,424 shares of the medical research company's stock worth $5,292,000 after buying an additional 1,017 shares in the last quarter. Finally, Pathstone Holdings LLC raised its stake in shares of Amgen by 1.7% during the 3rd quarter. Pathstone Holdings LLC now owns 98,605 shares of the medical research company's stock worth $31,772,000 after buying an additional 1,694 shares in the last quarter. 76.50% of the stock is owned by hedge funds and other institutional investors.

Amgen Trading Up 0.4 %

Shares of AMGN stock traded up $1.19 during mid-day trading on Tuesday, hitting $279.95. 3,210,343 shares of the company's stock were exchanged, compared to its average volume of 2,459,217. Amgen Inc. has a fifty-two week low of $260.52 and a fifty-two week high of $346.85. The stock has a 50-day simple moving average of $318.92 and a two-hundred day simple moving average of $318.43. The company has a quick ratio of 0.96, a current ratio of 1.32 and a debt-to-equity ratio of 7.55. The stock has a market cap of $150.48 billion, a price-to-earnings ratio of 35.85, a PEG ratio of 2.53 and a beta of 0.60.

Amgen (NASDAQ:AMGN - Get Free Report) last posted its quarterly earnings data on Wednesday, October 30th. The medical research company reported $5.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.11 by $0.47. Amgen had a return on equity of 168.35% and a net margin of 13.00%. The business had revenue of $8.50 billion for the quarter, compared to analysts' expectations of $8.50 billion. During the same quarter last year, the firm earned $4.96 earnings per share. The business's revenue was up 23.2% on a year-over-year basis. Equities analysts expect that Amgen Inc. will post 19.51 EPS for the current fiscal year.

Amgen Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, December 9th. Stockholders of record on Monday, November 18th will be issued a dividend of $2.25 per share. This represents a $9.00 dividend on an annualized basis and a dividend yield of 3.21%. The ex-dividend date is Monday, November 18th. Amgen's payout ratio is currently 115.24%.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on AMGN. Royal Bank of Canada reissued an "outperform" rating and set a $362.00 target price on shares of Amgen in a research note on Thursday, September 26th. Barclays upped their price target on Amgen from $300.00 to $315.00 and gave the stock an "equal weight" rating in a report on Monday, October 7th. Citigroup started coverage on Amgen in a report on Thursday, November 14th. They issued a "neutral" rating and a $335.00 price target on the stock. Cantor Fitzgerald restated an "overweight" rating and issued a $405.00 price target on shares of Amgen in a report on Tuesday, October 22nd. Finally, Robert W. Baird restated an "underperform" rating and issued a $215.00 price target on shares of Amgen in a report on Wednesday, September 25th. One investment analyst has rated the stock with a sell rating, thirteen have given a hold rating, eleven have given a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $333.57.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.